Targeting cancer with power and precision


Sesen Bio, Inc. (NASDAQ: SESN), previously Eleven Biotherapeutics, Inc., is a late-stage company developing next-generation antibody-drug conjugate (ADC) therapies for patients with cancer. Their approach aims to overcome limitations of traditional ADCs by incorporating a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively, effectively and broadly kill cancer cells while sparing healthy cells. These single protein molecules are known as fusion proteins. Their lead program, Vicinium™, is a novel fusion protein currently in Phase 3 development for the treatment of patients with non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin (BCG).


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.sesenbio.com

Recent News

August 9, 2018
Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer

August 7, 2018
Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month Vista Trial Data and Regulatory Submission in 2019

August 2, 2018
Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner

Abbie Celniker, Ph.D.
Partner